Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Airleaf: BI 1291583 dose-finding in non-cystic fibrosis bronchiectasis
jRCT2041220074Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of verducatib in bronchiectasis (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Time to first pulmonary exacerbation. Started Oct 2022; status: active, not recruiting.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on jRCT2041220074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220074.